A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase …
JI Geller, E Fox, BK Turpin, SL Goldstein, X Liu… - Cancer, 2018 - Wiley Online Library
Background Axitinib is an oral small molecule that inhibits receptor tyrosine kinases vascular
endothelial growth factor receptors 1 to 3. A phase 1 and pharmacokinetic (PK) trial …
endothelial growth factor receptors 1 to 3. A phase 1 and pharmacokinetic (PK) trial …
[HTML][HTML] Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
LP Martin, MF Kozloff, RS Herbst, TA Samuel… - British journal of …, 2012 - nature.com
Background: Axitinib, a potent and selective second-generation inhibitor of vascular
endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human …
endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human …
Pharmacokinetic evaluation of axitinib
B Patson, RB Cohen, AJ Olszanski - Expert Opinion on Drug …, 2012 - Taylor & Francis
Introduction: The role of angiogenic inhibitors is clearly established in the treatment of
diverse malignancies. The field of antiangiogenesis is expanding rapidly, with an increasing …
diverse malignancies. The field of antiangiogenesis is expanding rapidly, with an increasing …
Axitinib (AG-013736)
RJ Kelly, O Rixe - Small molecules in oncology, 2010 - Springer
The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK)
signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes …
signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes …
Pharmacokinetics of single-agent axitinib across multiple solid tumor types
MA Tortorici, EEW Cohen, YK Pithavala… - Cancer chemotherapy …, 2014 - Springer
Purpose Axitinib, a potent and selective inhibitor of vascular endothelial growth factor
receptors, showed antitumor activity as a single agent against several solid tumor types in …
receptors, showed antitumor activity as a single agent against several solid tumor types in …
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor …
DD Hu-Lowe, HY Zou, ML Grazzini, ME Hallin… - Clinical Cancer …, 2008 - AACR
Abstract Purpose: Axitinib (AG-013736) is a potent and selective inhibitor of vascular
endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clinical …
endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clinical …
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
TK Choueiri - Current opinion in investigational drugs (London …, 2008 - europepmc.org
Axitinib is an oral inhibitor of the VEGF, PDGF and colony stimulating factor-1 receptor
tyrosine kinases and is currently in development by Pfizer Inc for the potential treatment of …
tyrosine kinases and is currently in development by Pfizer Inc for the potential treatment of …
Clinical pharmacology of axitinib
Y Chen, MA Tortorici, M Garrett, B Hee… - Clinical …, 2013 - Springer
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth
factor receptors 1, 2, and 3 that is approved in the US and several other countries for …
factor receptors 1, 2, and 3 that is approved in the US and several other countries for …
Effect of renal impairment on the pharmacokinetics and safety of axitinib
Background Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is
approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents …
approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents …
[HTML][HTML] A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal …
Background Axitinib and bevacizumab are targeted therapies against the vascular
endothelial growth factor pathway. Methods Patients with previously treated solid tumors …
endothelial growth factor pathway. Methods Patients with previously treated solid tumors …